Pulse Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Pulse Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $676 per $100 of sales comes from others' credit, against $225 from others' credit three years earlier. Less money tied up than almost all Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-212.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 89% of Healthcare companies in United States.
Cash Locked Ratio
−$676Money owed to suppliers is larger than money owed by customers plus stock: $676 per $100 of sales comes from others' credit, against $225 from others' credit three years earlier.
Less money tied up than almost all Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 50%
Sales fell 50% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-50% / +21%In 3 years sales changed by -50% while total assets changed by +21%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-34.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 66% of Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 64% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 78% of Healthcare companies in United States.
Tangible Net Worth Ratio
96%Of every $100 of net worth, $96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 82% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Pulse Biosciences, Inc. made a loss over the last year. Pulse Biosciences, Inc. owes $0.14 for every $1 it owns. Pulse Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPulse Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
37.76The share price is 37.76 times Pulse Biosciences, Inc.'s book value per share, higher than 97% of Healthcare companies in United States.
Market cap
$3.8 BThe total market value of all of Pulse Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$100 MWhat Pulse Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.40Net worth divided by the number of shares. The share price of $52.68 is 37.8 times this, which is the P/B above.
Return on equity (ROE)
-78.5%Pulse Biosciences, Inc. lost 78.5% of its shareholders' money over the last year, lower than 64% of Healthcare companies in United States.
Owes vs Owns
0.14×Pulse Biosciences, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Dividend yield
NonePulse Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossPulse Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-20794.6%Pulse Biosciences, Inc. lost $20795 for every $100 of revenue.
Cash vs debt
Net cashPulse Biosciences, Inc. held $73 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Pulse Biosciences, Inc.: $3.8 B ÷ $100 M (30 Jun 2026) = 37.8.
What is Pulse Biosciences, Inc.'s return on equity?
Pulse Biosciences, Inc. lost 78.5% of its shareholders' money over the last year, lower than 64% of Healthcare companies in United States.
How much does Pulse Biosciences, Inc. owe compared with what it owns?
Pulse Biosciences, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Does Pulse Biosciences, Inc. pay a dividend?
No. Pulse Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.